During the recent session, Aprea Therapeutics, Inc. (NASDAQ:APRE)’s traded shares were 11,545,211, with the beta value of the company hitting 0. At the last check, the stock’s price was $5.55, reflecting an intraday gain of 14.76% or $0.71. The 52-week high for the APRE share is $41.12, that puts it down -640.9% from that peak though still a striking +16.4% gain since the share price plummeted to a 52-week low of $4.64. The company’s market capitalization is $112.93 Million, and the average intraday trading volume over the past 10 days was 449.45 Million shares, and the average trade volume was 1.39 Million shares over the past three months.
Aprea Therapeutics, Inc. (APRE) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 2.8. APRE has a Sell rating from none of the analyst(s) out of 5 analysts who have looked at this stock. 4 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 1 recommend a Buy rating for it. None of the analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.49.
Aprea Therapeutics, Inc. (NASDAQ:APRE): Trading Information
Aprea Therapeutics, Inc. (APRE) registered a 14.76% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.61% in intraday trading to $5.75- this Thursday, Apr 08, hitting a weekly high. The stock’s 5-day price performance is 9.8%, and it has moved by 5.26% in 30 days. Based on these gigs, the overall price performance for the year is 13.82%. The short interest in Aprea Therapeutics, Inc. (NASDAQ:APRE) is 1.31 Million shares and it means that shorts have 0.94 day(s) to cover.
The consensus price target of analysts on Wall Street is $7.2, which implies an increase of 29.73% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $10 respectively. As a result, APRE is trading at a discount of 80.18% off the target high and 8.11% off the low.
Aprea Therapeutics, Inc. (APRE) projections and forecasts
An analysis of the company’s performance over the past 5 years shows that the company’s earnings fell an estimated 0%. While earnings are projected to return -89.9% in 2021, the next five years will return 0% per annum.
Aprea Therapeutics, Inc. (NASDAQ:APRE)’s Biggest Investors
Aprea Therapeutics, Inc. insiders own 23.34% of total outstanding shares while institutional holders control 57.5%, with the float percentage being 75.01%. Versant Venture Management, LLC is the largest shareholder of the company, while 110 institutions own stock in it. As of Dec 30, 2020, the company held over 1.43 Million shares (or 6.73% of all shares), a total value of $7.02 Million in shares.
The next largest institutional holding, with 1.38 Million shares, is of 5AM Venture Management, LLC’s that is approximately 6.5% of outstanding shares. At the market price on Dec 30, 2020, these shares were valued at $6.78 Million.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Also, the Mutual Funds coming in first place with the largest holdings of Aprea Therapeutics, Inc. (APRE) shares are Vanguard Total Stock Market Index Fund and Artisan International Small-Mid Fund. Data provided on Dec 30, 2020 indicates that Vanguard Total Stock Market Index Fund owns about 482,121 shares. This amounts to just over 2.28 percent of the company’s overall shares, with a $2.37 Million market value. The same data shows that the other fund manager holds slightly less at 359.84 Thousand, or about 1.7% of the stock, which is worth about $1.77 Million.